A new study finds that early placement of IVC filters does not reduce the risk of pulmonary embolism or death in patients who have suffered severe trauma.…
European regulators have placed new restrictions on the use of Xeljanz while they continue to review potential pulmonary embolism risks.…
Xeljanz side effects may increase the risk of pulmonary embolism by a factor of five when taken at higher doses, according to the preliminary findings of a clinical trial.…
Pfizer is suing Ajanta Pharma over plans to release a generic version of Xeljanz years before its patent protection is scheduled to run out.…
Xeljanz side effects can cause pulmonary embolism at high doses, European drug regulators warn.…
Federal health officials indicate that side effects of Xeljanz, a popular rheumatoid arthritis and ulcerative colitis drug, may increase the risk of blood clots in the lungs, potentially resulting in a pulmonary embolism or death. The FDA’s Xeljanz warning was issued Monday, after a recent clinical trial found that patients taking certain dosage amounts of Xeljanz for rheumatoid arthritis were found to be more likely to develop blood clots or die, when compared to individuals taking the same doses of the drug to treat ulcerative colitis. Xeljanz (tofacitinib) is a drug that was first approved by the FDA in 2012…
A new study warns that IVC filters are linked to an increased risk of death among pulmonary embolism patients.…
A new study found that Xarelto failed to prevent deaths from heart disease and heart failure.…
A new study finds that Xarelto appears to be relatively ineffective in preventing blood clot-related problems in recently hospitalized patients.…
Transgendered persons taking cross-sex estrogen hormones may be at an increased risk of blood clots and strokes, according to the findings of a new study.…
